2m 2m 2m 2m 2m 2m 2m
Regen BioPharma (RGBP)
OTC
$0.0003-$0.00005 (-18.64%)
Price as of Jun 03, 2026- $153,587.00Market Cap
- -98.95%1-Year Change
- BiotechnologyIndustry
Regen BioPharma (RGBP)
$0.0003-$0.00005 (-18.64%)
Annual
Quarterly
09/30/2025 | 09/30/2024 | 09/30/2023 | 09/30/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 17,733 +2,248.74% | 755 -99.40% | 126,560 +0.83% | 125,517 +105.11% | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 17,733 +2,248.74% | 755 -99.40% | 126,560 +0.83% | 125,517 +105.11% | |
Sales and Marketing Expense | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Research and Development Expense | -11,725 N/A | N/A N/A | -212,297 +34.25% | -158,138 +330.85% | |
Depreciation and Amortization Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Operating Expenses | 575,101 -12.03% | 653,781 -29.21% | 923,509 +60.58% | 575,122 +54.62% | |
Operating Profit | -1.3M +205.47% | -417,221 -39.26% | -686,950 +102.28% | -339,605 +69.15% | |
Interest Income | N/A N/A | N/A N/A | 0 N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | -58,584 -57.77% | -138,720 -56.10% | |
Interest Income and Expense and Net | 0 N/A | 0 +100.00% | -58,584 -57.77% | -138,720 -56.10% | |
Total Nonoperating Income and Expense | N/A N/A | N/A N/A | 1.8M +405,055.16% | 455 +97.83% | |
Income before Taxes | -1.3M +90.72% | -668,255 -165.29% | 1.0M -54.04% | 2.2M +132.92% | |
Income Taxes | 0 N/A | N/A N/A | N/A N/A | N/A N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -1.3M +90.72% | -668,255 -157.78% | 1.2M -52.67% | 2.4M +136.12% | |
Net Income from Continuing Operations Applicable to Common | -1.3M +90.72% | -668,255 -165.29% | 1.0M -54.04% | 2.2M +132.92% | |
Basic EPS and Net Income | -0.05 -68.75% | -0.16 -155.17% | 0.29 N/A | N/A N/A | |
Diluted EPS and Net Income | -0.05 -68.75% | -0.16 -155.17% | 0.29 N/A | N/A N/A | |
Basic Weighted Average Shares | 23.5M +472.27% | 4.1M +16.21% | 3.5M -99.92% | 4.7B +56.19% | |
Diluted Weighted Average Shares | 23.5M +472.27% | 4.1M +16.21% | 3.5M -99.92% | 4.7B +56.19% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 69,555 +9,614.39% | 716 -99.41% | 121,037 +136.38% | 51,204 -92.96% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 69,555 +9,614.39% | 716 -99.41% | 121,037 +136.38% | 51,204 -92.96% | |
Total Current Assets | 274,628 +91.58% | 143,351 +9.40% | 131,037 -61.05% | 336,422 -66.16% | |
Accumulated Depreciation | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Assets | N/A N/A | N/A N/A | 222,580 0.00% | 222,580 +2.11% | |
Total Assets | 274,628 +70.49% | 161,084 -54.45% | 353,617 -36.74% | 559,002 -53.88% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | 1.4M 0.00% | 1.4M +1,404.18% | 95,710 -95.73% | 2.2M +3.14% | |
Total Current Liabilities | 6.6M +21.89% | 5.4M +1.33% | 5.3M -38.24% | 8.6M -41.52% | |
Total Long-Term Debt | 1.2M +244.72% | 350,000 -46.11% | 649,494 -48.58% | 1.3M -64.53% | |
Total Long-Term Liabilities | 2.1M +48.11% | 1.4M +838.48% | 149,614 -95.79% | 3.6M -57.31% | |
Total Liabilities | 6.6M +21.89% | 5.4M -1.45% | 5.5M -36.50% | 8.6M -41.52% | |
Retained Earnings | -21.7M +6.24% | -20.4M +3.38% | -19.7M -5.53% | -20.9M -10.47% | |
Total Stockholders Equity | -6.3M N/A | N/A N/A | -5.1M -36.49% | -8.0M -40.41% | |
Total Shares Outstanding | 39.4M +648.82% | 5.3M +49.96% | 3.5M -99.93% | 5.0B +15.65% | |
Cash Flow | |||||
Cash from Operating Activities | -383,591 -48.96% | -751,536 +332.12% | -173,917 -128.66% | 606,921 +153.67% | |
Capital Expenditures | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Investing Activities | N/A N/A | N/A N/A | 25,000 0.00% | 25,000 -94.95% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 452,430 -28.32% | 631,215 +158.96% | 243,750 +359.21% | -94,036 -106.90% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | -7,187.18% -86.99% | -55,261.06% +10,081.00% | -542.79% +100.61% | -270.56% -17.53% | |
Return on Assets | -585.02% +125.30% | -259.67% -202.45% | 253.45% -8.15% | 275.93% +127.23% | |
Return on Equity | N/A N/A | N/A N/A | -17.60% -22.48% | -22.71% -134.94% | |
Revenue Growth | 2,248.74% +2,362.24% | -99.40% -12,061.90% | 0.83% -99.21% | 105.11% +336.91% | |
Current Ratio | 0.04 +56.93% | 0.03 +8.10% | 0.02 -36.83% | 0.04 -42.16% | |
Cash Ratio | 0.01 +10,500.00% | 0.0001 -99.56% | 0.02 +280.00% | 0.006 -87.88% | |
Debt-to-Equity Ratio | -0.42 N/A | N/A N/A | -0.15 -66.50% | -0.44 +2.54% | |
Debt-to-Assets Ratio | 9.64 -13.27% | 11.11 +427.19% | 2.11 -66.36% | 6.26 +32.49% | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow